Adicet Bio Inc
ACET
Market Cap$55.4M
Close$
$0.45
6.6% downside
Current Fair Value
6.6% downsideOvervalued by 6.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $55.40 Million |
|---|---|
| Enterprise Value | $16.14 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.33 |
| Beta | 1.64 |
| Outstanding Shares | 90,846,293 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.52 |
|---|---|
| PEG | 1.34 |
| Price to Sales | - |
| Price to Book Ratio | 0.24 |
| Enterprise Value to Revenue | 1.25 |
| Enterprise Value to EBIT | -0.12 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.07 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Adicet Bio Inc
82 employees
CEO: Chen Schor Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of 'off-the-shelf' gamma delta T cells, engineered with chimeric...